Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

betamethasone-calcipotriene topical

betamethasone-calcipotriene topical
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Wynzora CREAM, TOPICAL 0.064 %-0.005 %    
Taclonex OINTMENT, TOPICAL 0.064 %-0.005 %    
Taclonex SUSPENSION, TOPICAL 0.064 %-0.005 %    
Comments:

Taclonex ointment is non-formulary, not stocked.

Interchange to fluocinonide 0.05% ointment (see betamethsone topical interchange) and calcipotriene 0.005% ointment separately, request to defer initiation to outpatient therapy, or encourage patient to use home supply.

Taclonex suspension is also non-formulary, not stocked. Dispense betamethasone dipropionate 0.05% lotion in its place (without calcipotriene in the inpatient setting).

 

Wynzora: Interchange to fluocinonide 0.05% cream (see betamethsone topical interchange) and calcipotriene 0.005% cream separately. Inpatients may use home supply.

Reviewed: April 25, 2006 (Ointment) and May 26, 2009 (Suspension), June 2023 (Wynzora)

Spotlight Betamethasone/Calcipotriene Cream (Wynzora)

Last updated: Aug. 28, 2023






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved